The objective of the program is to create a cutting-edge research center focused on developing new therapeutic possibilities for multiple sclerosis (MS), an immune –mediated inflammatory brain disease that most dramatically affects people of working age. The intravenous application of human monoclonal antibodies directed against oligodendrocytes or neurons will be tested on animal models with the aim of inducing immunomodulation and neuroregeneration of the central nervous system. These antibodies have already shown efficacy in various models of multiple sclerosis. Based on the evaluation of parameters of safety and effectiveness, this method will be modified for use in patients suffering from refractory MS. The main research part will be conducted at Mayo Clinic by Dr. Orhun H. Kantarci, a recognized multiple sclerosis expert from Mayo Clinic.
From mid-May FNUSA-ICRC will be led by Slovenian neurologist Gorazd Stokin More
Invitation: Mendel Lecture "Genome stability and the control of recombination" More